Back to Stocks

LMAT

LEMAITRE VASCULAR INC
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

LeMaitre Vascular is demonstrating a powerful combination of operational leverage and strategic execution.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline margin growth, a closer look at the financials reveals structural vulnerabilities.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every LMAT filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads between aggressive growth and financial restructuring. On one hand, the fundamental business metrics are impressive, with double-digit revenue growth and a significant leap in net income to $15.7 million. The transition to direct sales and the consolidation of manufacturing in Burlington are clear strategic wins intended to lock in long-term margin improvements. The company is effectively utilizing its balance sheet to return capital via dividends and a new buyback authorization. However, the long-term outlook depends on the company's ability to manage its debt and currency risks. The convertible notes represent a looming overhang that could pressure the stock if not handled carefully. Investors must weigh the immediate operational success of the product launches and margin expansion against the structural risks of the debt stack and the volatility of international exchange rates. Overall, the filing indicates a company that is successfully growing its top and bottom lines, but one that remains sensitive to macroeconomic headwinds and capital structure complexities.

Selected Quarter

Core Takeaway

LeMaitre is successfully scaling its high-margin biologic products and direct sales, but investors must monitor the 2028 convertible note maturity.

Investor Lens

The trade-off is between immediate operational excellence and long-term capital structure risk.

Watch Next

The progress of the Burlington tissue-processing migration and the execution of the $100M buyback program.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.45Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 6

Gross margin increased by 350 basis points to 72.7% due to product mix and pricing.

margin expansion
90%
bullishMay 6

Net income grew 42% year-over-year to $15.7 million.

earnings beat
80%
bullishMay 6

Board authorized up to $100 million in common stock repurchases.

buyback
70%
bearishMay 6

Large $172.5 million convertible note stack creates potential future dilution.

dilution risk
60%
bullishMay 6

Gross margin increased by 350 basis points to 72.7% due to product mix and pricing.

margin expansion
90%
bullishMay 6

Net income grew 42% year-over-year to $15.7 million.

earnings beat
80%
bullishMay 6

Board authorized up to $100 million in common stock repurchases.

buyback
70%
bearishMay 6

Large $172.5 million convertible note stack creates potential future dilution.

dilution risk
60%
bullishMay 6

Gross margin increased by 350 basis points to 72.7% due to product mix and pricing.

margin expansion
90%
bullishMay 6

Net income grew 42% year-over-year to $15.7 million.

earnings beat
80%
bullishMay 6

Board authorized up to $100 million in common stock repurchases.

buyback
70%
bearishMay 6

Large $172.5 million convertible note stack creates potential future dilution.

dilution risk
60%
bullishMay 6

Gross margin increased by 350 basis points to 72.7% due to product mix and pricing.

margin expansion
90%
bullishMay 6

Net income grew 42% year-over-year to $15.7 million.

earnings beat
80%
bullishMay 6

Board authorized up to $100 million in common stock repurchases.

buyback
70%
bearishMay 6

Large $172.5 million convertible note stack creates potential future dilution.

dilution risk
60%
bullishMay 6

Gross margin increased by 350 basis points to 72.7% due to product mix and pricing.

margin expansion
90%
bullishMay 6

Net income grew 42% year-over-year to $15.7 million.

earnings beat
80%
bullishMay 6

Board authorized up to $100 million in common stock repurchases.

buyback
70%
bearishMay 6

Large $172.5 million convertible note stack creates potential future dilution.

dilution risk
60%
bullishMay 6

Gross margin increased by 350 basis points to 72.7% due to product mix and pricing.

margin expansion
90%
bullishMay 6

Net income grew 42% year-over-year to $15.7 million.

earnings beat
80%
bullishMay 6

Board authorized up to $100 million in common stock repurchases.

buyback
70%
bearishMay 6

Large $172.5 million convertible note stack creates potential future dilution.

dilution risk
60%
bullishMay 6

Gross margin increased by 350 basis points to 72.7% due to product mix and pricing.

margin expansion
90%
bullishMay 6

Net income grew 42% year-over-year to $15.7 million.

earnings beat
80%
bullishMay 6

Board authorized up to $100 million in common stock repurchases.

buyback
70%
bearishMay 6

Large $172.5 million convertible note stack creates potential future dilution.

dilution risk
60%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing presents a company at a crossroads between aggressive growth and financial restructuring. On one hand, the fundamental business metrics are impressive, with double-digit revenue growth and a significant leap in net income to $15.7 million. The transition to direct sales and the consolidation of manufacturing in Burlington are clear strategic wins intended to lock in long-term margin improvements. The company is effectively utilizing its balance sheet to return capital via dividends and a new buyback authorization. However, the long-term outlook depends on the company's ability to manage its debt and currency risks. The convertible notes represent a looming overhang that could pressure the stock if not handled carefully. Investors must weigh the immediate operational success of the product launches and margin expansion against the structural risks of the debt stack and the volatility of international exchange rates. Overall, the filing indicates a company that is successfully growing its top and bottom lines, but one that remains sensitive to macroeconomic headwinds and capital structure complexities.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.